Derek J Maetzold sold $1.1M of CSTL
Pres. & Chief Exec. Officer at CASTLE BIOSCIENCES INC. 44,125 shares at an average of $25.67, traded Mar 11, 2026, filed Mar 13, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.1M at market
- +10Share of holdings soldSold 39% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.5%, 3m -19.0%, 6m +26.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-017694, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | MOption exercise Common Stock10b5-1 | +6,226 | $2.39 | $15k | 112,047 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stock10b5-1 | -17,310 | $26.11 | $452k | 94,737 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stockindirect: By The Maetzold Descendants 2020 Trust10b5-1 | -1,357 | $26.11 | $35k | 51,566 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stockindirect: By Derek Maetzold 2020 Irrevocable Trust10b5-1 | -1,160 | $26.11 | $30k | 43,826 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stockindirect: By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk10b5-1 | -282 | $26.11 | $7,363 | 3,336 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stockindirect: By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold10b5-1 | -279 | $26.11 | $7,284 | 3,336 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stockindirect: By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold10b5-1 | -279 | $26.11 | $7,284 | 3,336 | Mar 13, 2026 |
| Mar 11, 2026 | SOpen-market sale Common Stockindirect: By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold10b5-1 | -279 | $26.11 | $7,284 | 3,336 | Mar 13, 2026 |
| Mar 12, 2026 | SOpen-market sale Common Stock10b5-1 | -23,179 | $25.28 | $586k | 71,558 | Mar 13, 2026 |
| Mar 11, 2026 | MOption exercise Stock option (right to buy)derivative10b5-1 | -6,226 | $0.00 | $0 | 14,282 | Mar 13, 2026 |
Related signals
Other insiders at CASTLE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $516k 14,496 shares | -49% | |
| 16Weak | CASTLE BIOSCIENCES INC | Kristen M Oelschlager Chief Operating Officer | $149k 4,153 shares | -24% | |
| 28Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $232k 6,577 shares | -11% | |
| 33Weak | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $512k 14,496 shares | -48% | |
| 27Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $223k 6,600 shares | -10% | |
| 32Weak | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $465k 14,518 shares | -48% | |
| 16Weak | CASTLE BIOSCIENCES INC | Kristen M Oelschlager Chief Operating Officer | $139k 4,152 shares | -24% | |
| 17Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $57k 1,730 shares | -3% | |
| 45Moderate | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $616k 18,560 shares | -55% | |
| 29Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $317k 9,050 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.